CE Marking Versus FDA Clearance: Two Routes a Medical Device Takes to Market

A CE mark and an FDA clearance both mean a medical device cleared a regulatory bar before it could be sold, but the two bars are set in different places, and neither one is a promise that the product outperforms its alternatives. The most useful way to read either label is to ask a narrow question: what, exactly, did this route require the manufacturer to prove? In the United States the answer depends on which of three FDA pathways the device took. In the European Union the answer turns on conformity with the applicable regulation, often checked by an independent body rather than by a government agency. A product sold on both sides of the Atlantic has satisfied two separate rulebooks, which is why the same device legitimately carries both marks and why the two cannot be treated as interchangeable.

Key points#

• A regulatory mark tells you a device met a defined minimum for its risk class, not that it is the best option available.
• The US uses three routes: 510(k) clearance (similarity to an existing device), De Novo (a new low-to-moderate-risk category), and PMA (a full safety and effectiveness review).
• In the US, "cleared" and "approved" are not synonyms, and the difference is meaningful.
• In the EU, CE marking is a conformity declaration; for the lowest-risk devices the manufacturer can self-declare with no outside reviewer.
• "FDA cleared" and "CE marked" each describe a floor a product had to reach, defined by its route, not the size of its evidence base.

Start with the label, not the logo#

A regulatory mark is a floor, not a ranking. It says a device met the minimum a specific route demanded for a specific risk class. It does not say the device beat its competitors, and it does not tell you how large or how rigorous the underlying study was. Two products can share the same mark while resting on very different amounts of evidence, because the route, not the manufacturer's ambition, sets the requirement. Reading a device claim well means matching the mark to the question its route was designed to answer, then asking whether that question is the one you actually care about.

The United States: three routes, two verbs#

The FDA sorts devices into three risk classes and pairs each with a pathway. The vocabulary is worth slowing down on, because "cleared" and "approved" carry different weight.

510(k) clearance#

Most moderate-risk devices enter the US market through a 510(k), a premarket notification. The central test is substantial equivalence: is this device at least as safe and effective as a legally marketed predicate that shares its intended use and comparable technology? Submissions often lean on bench testing, biocompatibility, and engineering data, with clinical data requested only when nonclinical methods cannot settle a performance question. Clearance therefore certifies a comparison rather than a fresh, from-scratch demonstration of benefit. For well-understood device types that is a sensible shortcut, and it is also the limit you should keep in mind: the bar is equivalence to something already trusted, not proof of a new health outcome.

De Novo#

Sometimes a device is only low or moderate risk yet has no suitable predicate to compare against because it is genuinely new. The De Novo route lets the FDA place such a device into Class I or II, create a fresh product code, and set special controls that later devices of the same type must meet. It bridges the gap between "similar enough for a 510(k)" and "risky enough for the most demanding pathway."

Premarket Approval#

For the highest-risk devices, typically Class III products that support or sustain life or carry serious potential for harm, Premarket Approval (PMA) is the strictest route. Here the FDA reviews the device on its own evidence of safety and effectiveness, usually including clinical data, design validation, and a manufacturing inspection. This is the pathway the agency calls "approval," and it is the closest US analogue to showing a benefit directly rather than by analogy to another product.

The European Union: conformity, not endorsement#

CE marking works from a different premise. It is a declaration that the device conforms to the applicable EU regulation, most often the Medical Device Regulation (MDR) or, for tests run on samples taken from the body, the In Vitro Diagnostic Regulation (IVDR). Under the MDR the manufacturer must meet the General Safety and Performance Requirements, run a quality management system, and build a clinical evaluation that links the device's claims to evidence. For the lowest-risk devices the manufacturer can self-declare conformity with no third party involved. For higher-risk classes an independent organization called a notified body reviews the technical file, the quality system, or both, and issues a certificate. A notified body is not a state regulator; it is an accredited private organization designated to assess devices against the regulation.

Two European details cause the most confusion. First, the split between the MDR and the IVDR: the IVDR sharply raised the share of diagnostics that need notified-body involvement and defined companion diagnostics (tests that guide whether a specific therapy fits a patient) as a category with its own evidence expectations. Second, CE marking is not a one-time gate. It comes bundled with post-market surveillance and vigilance duties, so the manufacturer has to keep gathering real-world safety data and report serious incidents after the device is on the market.

Why one product carries two different marks#

Building a device once does not merge the two systems into a single question. The EU asks whether the device conforms to the regulation's safety and performance requirements, backed by a clinical evaluation and, for most classes, a notified body signing off on the file. The US asks, depending on class, whether the device is equivalent to a predicate, deserves a new low-to-moderate-risk classification, or survives an independent safety and effectiveness review. The two overlap in spirit, since both care about safety, both demand evidence, and both require post-market monitoring, but they are not identical and their labels do not transfer. A CE mark does not mean the FDA looked at the device, and an FDA clearance does not mean a notified body certified it.

That is also why device marketing rewards a careful reader. "FDA cleared" through a 510(k) is a real status, but it signals substantial equivalence, not a full effectiveness trial. "CE marked" signals conformity with the relevant EU regulation, which for a self-declared low-risk product involved no outside reviewer at all. On its own, neither phrase reveals how much clinical evidence stands behind the device.

Software and tests that keep changing#

The logic gets an extra twist for software that functions as a medical device. Both systems are still adapting to products that update often, learn from new data, and blur the line between a tool and a diagnosis. A mark earned by one version of an algorithm may not describe the version a patient uses months later, which is exactly why post-market obligations and clear labeling matter for this category. Knowing which route a product took, and what that route was built to check, is the first step in reading its claims accurately.